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Abstract
Background: The GDNF family ligands (GFLs) are regulators of neurogenic inflammation and pain. We have
previously shown that GFLs increase the release of the sensory neuron neuropeptide, calcitonin gene-related
peptide (CGRP) from isolated mouse DRG.
Results: Inhibitors of the mitogen-activated protein kinase (MAPK) pathway abolished the enhancement of CGRP
release by GDNF. Neurturin-induced enhancement in the stimulated release of CGRP, used as an indication of
sensory neuronal sensitization, was abolished by inhibition of the phosphatidylinositol-3 kinase (PI-3K) pathway.
Reduction in Ret expression abolished the GDNF-induced sensitization, but did not fully inhibit the increase in
stimulus-evoked release of CGRP caused by neurturin or artemin, indicating the presence of Ret-independent GFL-
induced signaling in sensory neurons. Integrin b-1 and NCAM are involved in a component of Ret-independent
GFL signaling in sensory neurons.
Conclusions: These data demonstrate the distinct and variable Ret-dependent and Ret-independent signaling
mechanisms by which GFLs induce sensitization of sensory neurons. Additionally, there is a clear disconnect
between intracellular signaling pathway activation and changes in sensory neuronal function.
Background
The glial cell line-derived neurotrophic factor (GDNF)
family ligands (GFLs) are a group of small peptides in
the TGFb super-family of molecules. They exist natu-
rally as homodimers and include GDNF, neurturin
( N R T N ) ,a r t e m i n( A R T N ) ,a n dp e r s e p h i n[ P S P N ;1 ,2 ] .
There is direct evidence that the GFLs can alter channel
properties and the threshold of activation of sensory
neurons. Interestingly, application of GDNF, NRTN, and
ARTN enhance calcium influx through TRPV1 in sen-
sory neurons exposed to capsaicin, a specific exogenous
l i g a n df o rt h ec h a n n e l[ 3 ] .W eh a v ed e m o n s t r a t e dt h a t
t h ec h a n g ei ns e n s i t i v i t yo fsensory neurons elicited by
GDNF, NRTN, and ARTN results in increased release
of the neuropeptide, calcitonin gene-related peptide
[CGRP; 4], an important transmitter in neurogenic
inflammation and pain signaling.
Each of the GFLs has its own GDNF family receptor a
(GFRa) subtype to which it preferentially binds. The
action of the GFRa receptors, which are localized to
l i p i dr a f t sb yt h eG P I - a n c h o r s[ 5 ] ,i si n i t i a t e dw h e na
GFL homodimer approaches two GFRa receptors, of the
same isoform, and causes them to homodimerize [6].
This GFL-GFRa complex translocates to the Ret recep-
tor tyrosine kinase and causes a dimerization of Ret,
which initiates a number of intracellular signaling path-
ways [6]. The intracellular signaling pathways initiated
by Ret are diverse, including MEK-Erk 1/2 [6,7], phospa-
tidylinositol-3 kinase (PI-3K) [8,9], Jun NH2-terminal
protein kinase [10], p38 MAPK [11], and phospholipase
C-gamma [PLC-g; 12]. There is evidence that activation
with different GFLs results in distinct Ret confirmations
and initiation of unique signaling cascades [13]. In addi-
tion, there is emerging evidence of GDNF-induced, Ret-
independent signaling through Src family kinases
(SFKs), and the MEK-Erk 1/2 and pCREB pathways [5].
Neural cell adhesion molecules (NCAMs) were the first
alternative GFRa-1 binding partners identified [14,15],
but GFRa-1 can bind with Integrin b1 as well [16].
Although there is no functional evidence of other Ret-
independent GFL-mediated actions, these data suggest
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neurons.
Here we demonstrate that each of the GFLs uses dis-
tinct intracellular signaling pathways to elicit sensory
neuronal sensitization, measured by enhancement in the
capsaicin stimulated-release of the sensory neuron neu-
ropeptide, CGRP. We are able to distinguish activation
of signaling pathways by the individual GFLs from the
pathways involved in sensoryn e u r o n a ls e n s i t i z a t i o n .
Additionally, we identify Ret-independent signaling
pathways initiated by NRTN and ARTN, which are
important in altering the function of peripheral sensory
neurons. These complements of signaling pathways
necessary for GFL-induced inflammation and pain sig-
naling are novel.
Results and Discussion
Ret-independent signaling pathways are responsible
for NRTN and ARTN-induced enhancement in the
release of iCGRP
Several studies indicate a Ret-independent component
to GFLs’ actions [14-17], although these studies provide
only indirect evidence of Ret-independent function. To
determine if Ret is necessary for the GFL-induced sensi-
tization of primary sensory neurons involved in neuro-
genic inflammation and pain modulation, the ability of
GFLs to enhance capsaicin-stimulated release of immu-
noreactive CGRP (iCGRP) in isolated mouse sensory
neurons with reduction in the expression of Ret was
examined. Capsaicin activates the TRPV1 receptor
expressed on peptide containing sensory neurons that
mostly fall into the category of small diameter nocicep-
tive neurons [18,19]. Our DRG preparation is a hetero-
geneous compilation of several different types of
neurons and glial cells. Almost all neurons that express
the TRPV1 receptor also express CGRP [20,3]. In addi-
tion, each of the specific GFRa subtypes is coexpressed
with TRPV1 at varying levels, with approximately
20-50% coexpression of GFRa-1 or GFRa-2 with
TRPV1 and a nearly 90% coexpression of GFRa-3 and
TRPV1 [3,21,22]. Our previous work demonstrates that
GDNF, NRTN and ARTN all enhance capsaicin-induced
release of iCGRP from these cultures, indicating the co-
expression of the three GFRa subtypes with TRPV1 in
significant subsets of peptide containing neurons in our
preparation [4]. In these cultures of dorsal root ganglia
(DRG) neurons, Ret levels were reduced with the use of
a specific pool of siRNA molecules directed at Ret, since
no specific pharmacological inhibitors of the activation
of this molecule exist. The siRNA pool (100 nM)
reduced the amount of Ret protein in the DRG cultures
by ~85%, while a scramble siRNA did not alter Ret
levels (Figure 1A and B). As shown in Figure 1, the
immunoband present in the lane loaded with the
purified Ret protein is at same location as the bands for
the DRG tissue probed with Ret antibody.
As we have previously demonstrated, exposure of
DRG cultures to GDNF, ARTN or NRTN (at 10 ng/ml
for 20 min) causes an approximate 2 fold increase in
capsaicin-stimulated release of iCGRP (Figure 1C).
These treatments do not alter resting levels of iCGRP
release or the total neuronal content of the peptide [4].
To determine whether Ret is necessary for GFL-induced
enhancement of iCGRP release, Ret siRNA (100 nM)
was added to the DRG in culture two days after plating
and remained in the culture media for 48 hours. Inter-
estingly, while the GDNF-induced sensitization of sen-
sory neurons was abolished when Ret siRNA was added,
NRTN and ARTN still elicited an increase in stimulated
peptide release (Figure 1C). The enhancement in stimu-
lated-evoked release of iCGRP by NRTN and ARTN,
while still present, was significantly reduced in the pre-
sence of Ret siRNA. The total content of iCGRP was
not affected by these manipulations. Therefore, Ret is
necessary for the enhanced stimulated-release of iCGRP
induced by GDNF and mediates a component of the
enhancement caused by NRTN and ARTN. The obser-
vation that NRTN and ARTN are still capable of enhan-
cing the stimulated-release of CGRP in sensory neurons
in cultures with greatly reduced Ret expression, suggests
that a component of the enhancement caused by NRTN
and ARTN is due to Ret-independent mechanisms.
One of the other possible binding partners of the
GFL-GFRa complexes is NCAM [15]. To investigate
whether or not NCAM is involved in the NRTN and
ARTN-induced sensitization of DRG neurons, NCAM
levels were decreased using a pool of siRNA directed
towards NCAM p140. NCAM p140 is the intracellular
portion of this protein responsible for initiation of intra-
cellular signaling pathways, specifically the Fyn kinase
pathway [23]. The pool of NCAM siRNA reduced
NCAM p140 levels by ~75% in DRG cultures
(Figure 2A and 2B). The amount of NCAM present in
untreated and scramble siRNA treated DRG cultures
were not different. Additionally, reduction of the level of
NCAM by NCAM siRNA in the DRG cultures did not
prevent the GDNF-induced enhancement in the stimu-
lated-release of CGRP (Figure 2C).
DRG cultures were treated NCAM siRNA (50 nM)
and Ret siRNA (50 nM), to ensure the total amount of
siRNA present in the culture media was consistent
(100 nM) and the basal and stimulated-release of iCGRP
was measured in the presence of GFLs. Figure 3 shows
that GDNF-induced sensitization was abolished with
this combined siRNA treatment regimen, presumably
because the enhancement in stimulated-release of
iCGRP accomplished by GDNF is Ret-dependent, as
seen in Figure 1. The ARTN-induced sensitization,
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Page 2 of 22Figure 1 GDNF-induced enhancement in the stimulated-release of iCGRP is mediated by Ret-dependent pathways.A )T h i s
representative Western blot demonstrates that exposure of DRG to Ret siRNA decreases Ret levels, while scramble siRNA does not change Ret
levels. Additionally, a portion of the Ret protein, 31-330, is present on the immunoblot with a band the same size as Ret from DRG. B)
Densitometric analysis of three separate Western blots like that in A probing for Ret. C) Peptide release elicited by a 10 minute exposure to
Hepes buffer alone (open bar) or Hepes buffer containing 50 nM capsaicin (Cap; dark bars) is expressed as mean percent total peptide content
of cells in each well ± SEM (n = 12-18 wells per condition). Asterisks (*) indicate statistically significant differences in band density and iCGRP
release between treatment groups and the no GFL condition using an ANOVA with Dunnett’s post-hoc test (p < 0.05). Ampersands (@) indicate
statistically significant differences between the GFL treatment and the siRNA treated condition using a t-test (p < 0.05). In all cases, release
stimulated by capsaicin was significantly higher than basal release.
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Page 3 of 22Figure 2 ARTN-induced enhancement in the stimulated-release of iCGRP is mediated, in part, by NCAM-dependent pathways.A )T h i s
representative Western blot demonstrates that exposure of DRG to NCAM siRNA decreases NCAM levels, while scramble siRNA does not change
NCAM levels. B) Densitometric analysis of three separate Western blots like that in A probing for NCAM. C) Peptide release elicited by a 10
minute exposure to Hepes buffer alone (open bar) or Hepes buffer containing 50 nM capsaicin (Cap; dark bars) is expressed as mean percent
total peptide content of cells in each well ± SEM (n = 12-18 wells per condition). GFLs were included in the 10 minutes prior to and throughout
capsaicin exposure. Asterisks (*) indicate statistically significant differences in band density and iCGRP release between treatment groups and the
no GFL condition using an ANOVA with Dunnett’s post-hoc test (p < 0.05). Ampersands (@) indicate statistically significant differences between
the GFL treatment and the siRNA treated condition using a t-test (p < 0.05).
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Page 4 of 22while not eliminated by Ret siRNA treatment alone, was
completely abolished by NCAM and Ret siRNA treat-
ment in combination (10 ng/mL ARTN: 12.13 ±
0.91%,10 ng/mL ARTN and Ret + NCAM siRNA: 5.22
± 0.61%). NRTN-induced sensitization was not pre-
vented by NCAM and Ret siRNA treatment in combina-
tion. However, the enhancement of stimulated release of
iCGRP in response to NRTN was significantly lower
with the combined siRNA treatment (10 ng/mL NRTN:
9.09 ± 1.27%,10 ng/mL NRTN and Ret + NCAM
siRNA: 7.20 ± 0.37%). Treatment with NCAM siRNA
alone did not abolish NRTN or ARTN-induced sensiti-
zation, although these treatments did reduced the
amount of GFL-induced release, and NCAM siRNA
treatment alone did not affect GDNF-induced enhance-
ment in the stimulated-release of CGRP (Figure 2C).
Finally, the role of another receptor reported to be a
binding partner of the GFL-GFRa complex, Integrin b-
1, was investigated [16]. A pool of siRNA molecules
(100 nM) directed at Integrin b-1 was used in order to
inhibit its expression and this was verified with a Wes-
tern blot probing for the Integrin b-1 intracellular frag-
ment, which has a molecular weight of 130 kDa and is
the direct signaling portion of the molecule [24]. Figure
4A and 4B demonstrate that Integrin b-1 siRNA reduces
the level of expression of this receptor by ~65% in DRG
cultures.
When Integrin b-1 siRNA was added to DRG, NRTN-
induced sensitization remained, although the level of
enhancement in stimulated release of iCGRP was
reduced (Figure 4C). Integrin b-1 siRNA did not affect
the ARTN-induced enhancement in the stimulated-
release of CGRP. The total content of iCGRP was not
affected by these manipulations. This data indicates that
Integrin b-1 plays a role in NRTN-induced sensitization,
b u tt h a ti ti sn o tt h eo n l ym e c h a n i s mb yw h i c hN R T N
induces sensitization.
DRG cultures were then treated with Ret siRNA,
NCAM siRNA, and Integrin b-1 siRNA and exposed to
the GFLs to determine the role of these complements of
receptors in GFL-induced sensitization. DRG were trea-
ted with all three siRNA (33 nM each) on day 2, 4, and
6 after plating. This treatment regimen was followed to
ensure the total amount of siRNA present in the culture
media was consistent (100 nM) and that over the course
of the three treatments the cells were exposed to 100
nM of each siRNA. When all three pools of siRNA were
added to the DRG in culture, the basal-release of iCGRP
was not affected while the NRTN-induced sensitization
of stimulus-evoked release was abolished (Figure 4D).
The total content of iCGRP was not affected by these
m a n i p u l a t i o n s .T h e s ed a t ai n d i c a t et h a ta l lt h r e eo f
these receptors (Ret, NCAM, and Integrin b-1) are
important in NRTN-induced enhancement in the stimu-
lated-release of CGRP. There is a Ret-dependent
component, which contributes about half of the NRTN-
induced enhancement in the capsaicin stimulated-
release of iCGRP. Two Ret-independent pathways,
NCAM-dependent and Integrin b-1-dependent
pathways, account for the other components of the
NRTN-induced enhancement in the capsaicin stimu-
lated-release of iCGRP. However, it is necessary to
inhibit all three of these pathways to eliminate NRTN-
induced sensitization, which is a novel observation for
the mechanism of the GFL-induced actions on sensory
neurons. There are two possible scenarios to explain
this phenomenon. Either the GFRa-2 containing neu-
rons that respond to NRTN contain all three signaling
receptors (Ret, NCAM and Integrin b-1), each of which
play a role in the sensitizing action of NRTN on that
individual neuron or, alternatively, there are different
populations of GFRa-2 expressing neurons expressing
only one or two of the signaling receptors. For example,
when siRNA to Ret is used this eliminates the response
from neurons containing GFRa-2 and Ret but the activ-
ity of other neurons expressing GFRa-2 and NCAM
and/or Integrin b-1 is preserved.
Figure 3 ARTN-induced enhancement in the stimulated-release
of iCGRP is mediated by Ret-dependent and NCAM-dependent
pathways. Peptide release elicited by a 10 minute exposure to
Hepes buffer alone (open bar) or Hepes buffer containing 50 nM
capsaicin (Cap; dark bars) is expressed as mean percent total
peptide content of cells in each well ± SEM (n = 12-18 wells per
condition). Asterisks (*) indicate statistically significant differences in
iCGRP release between treatment groups and the no GFL condition
using an ANOVA with Dunnett’s post-hoc test (p < 0.05).
Ampersands (@) indicate statistically significant differences between
the GFL treatment and the siRNA treated condition using a t-test (p
< 0.05). In all cases, release stimulated by capsaicin was significantly
higher than basal release.
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Page 5 of 22Figure 4 NRTN-induced enhancement in the stimulated-release of iCGRP is mediated by Ret-dependent, NCAM-dependent, and
Integrin b-1-dependent pathways. A) This representative Western blot demonstrates that exposure of DRG to Integrin b-1 siRNA decreases
Integrin b-1 levels, while scramble siRNA does not change Integrin b-1 levels. B) Densitometric analysis of three separate Western blots like that
in A probing for Integrin b-1. C and D) Peptide release elicited by a 10 minute exposure to Hepes buffer alone (open bar) or Hepes buffer
containing 50 nM capsaicin (Cap; dark bars) is expressed as mean percent total peptide content of cells in each well ± SEM (n = 12-18 wells per
condition). Asterisks (*) indicate statistically significant differences in band density and iCGRP release between treatment groups and the no GFL
condition using an ANOVA with Dunnett’s post-hoc test (p < 0.05). Ampersands (@) indicate statistically significant differences between the GFL
treatment and the siRNA treated condition using a t-test (p < 0.05). In all cases, release stimulated by capsaicin was significantly higher than
basal release.
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Page 6 of 22Distinct signaling pathways are responsible for GFL-
induced enhancement in the release of iCGRP
Having established that selected GFLs induce sensitiza-
tion of sensory neurons through different complements
of cell surface receptors, the intracellular signaling path-
ways by which the GFLs induce sensitization were deter-
mined. Most of the evidence for the actions of the GFLs
on adult, mammalian neurons indicates that the follow-
ing signaling pathways are activated by GFL-induced
activation of Ret: MEK/Erk 1/2 pathway, the PI-3K
pathway, the Src kinase pathway, the Fyn pathway, and
the PKC pathway [25-28]. These same intracellular sig-
naling pathways are initiated by NCAM activation
[15,29] and Integrin b-1 activation [30].
Exposure of DRG cultures to 10 ng/mL GDNF for 10
minutes doubles immunreactive phospho-Erk (p-Erk)
levels compared to culture exposed to Hepes buffer
alone (Figure 5A). The GDNF-induced increase in p-Erk
was prevented by 10 μM PD98059 and 1.0 μM U0126,
two MEK inhibitors [31-34], but not by 10 μM U0124,
and inactive analog (Figure 5A and 5B). However,
GDNF did not increase the amount of immunoreactive
phospho-Akt (p-Akt; Figure 5A and 5C). Increases in
the level of p-Erk and p-Akt are used as surrogate mar-
kers for activation of the MEK/Erk1/2 and PI-3K path-
ways, respectively.
MEK inhibitors also prevented the GDNF-induced
increase in capsaicin-stimulated release of iCGRP from
sensory neurons. As seen in Figure 5D, the enhance-
ment in stimulated release of iCGRP induced by a 10
minute treatment with 10 ng/mL GDNF was abolished
by the MEK inhibitors PD98059 (10 μM) and U0126
(1.0 μM), but not by the inactive control U0124
(1.0 μM). The PI-3K inhibitor, LY294002 (10 μM), and
the inactive control for this compound, LY303511 (10
μM), did not affect the GDNF-induced enhancement in
the stimulated-release of CGRP (Figure 5D). Taken
together, these data indicate that GDNF-induced sensiti-
zation of sensory neurons occurs through activation of
the MEK/Erk 1/2 pathway and not the PI-3K pathway.
NRTN also has been shown to activate the MEK/Erk
1/2 and PI-3K pathways [35,36]. When DRG cultures
were exposed to 10 ng/mL NRTN for 10 minutes, both
p-Erk 1/2 and p-Akt levels were increased ~2 fold (Fig-
ure 6A). PD98059 (10 μM) and U0126 (1.0 μM) pre-
vented the NRTN-induced increased in p-Erk, while the
inactive analogue U0124 (1.0 μM) did not affect NRTN
increases in p-Erk (Figure 6A and 6B). Unlike GDNF,
exposure of DRG cultures to NRTN increased p-Akt
levels ~2 fold, and this increase was prevented by
LY294002 (10 μM) but not the inactive analog,
LY303511 (10 μM; Figure 6A and 6C). Interestingly,
NRTN-induced enhancement in the release of iCGRP
was abolished only by LY294002, the PI-3K inhibitor
(Figure 6D). Neither of the MEK/Erk 1/2 inhibitors pre-
vented NRTN-induced sensitization despite the fact that
they both inhibited NRTN-induced increases in p-Erk,
nor did the MEK/Erk 1/2 inhibitors affect the activation
of the PI-3K pathway. Therefore, while NRTN causes
increases in both p-Erk and p-Akt, only inhibition of the
PI-3K pathway prevents NRTN-induced sensitization in
our model of sensory neuronal sensitization. Although
NRTN activated the MEK/Erk 1/2 pathway, this path-
way is not responsible for NRTN-induced increases in
the stimulated release of CGRP. The ability of GDNF,
but not NRTN, to cause an increase in the stimulated
release of CGRP through this pathway that both GFLs
activate is interesting. While the mechanisms for this
signaling specificity are unknown, one potential explana-
tion is receptor-signaling complex compartmentaliza-
tion. For instance, GFRa-2 may be present primarily in
a cell membrane compartment with Ret, the compo-
nents of the PI-3K pathway, and the TRPV1 receptor,
but not the components of the MEK/Erk 1/2 pathway.
On the other hand, GFRa-1 may be present primarily in
a cell membrane compartment with Ret, the compo-
nents of the MEK/Erk 1/2 pathway, and the TRPV1
receptor, but not the components of the PI-3K pathway.
The specific intracellular signaling cascades responsible
for the effects of each of the GFLs on the stimulated
release of CGRP may depend upon the components pre-
sent in each particular cell membrane compartment.
This observation demonstrates a dissociation of
increases in levels of phosphorylated effector proteins
from a functional change within the cells in culture.
ARTN activates a number of intracellular signaling
pathways, including the MEK/Erk 1/2 and PI-3K path-
ways. These pathways also are associated with altered
functions in sensory neurons [36-38]. A 10 minute
exposure to 10 ng/mL ARTN, similar to NRTN,
increased both p-Erk and p-Akt levels by 2-3 fold when
compared to untreated cultures (Figure 7A, 7B and 7C).
Treatment with MEK inhibitors (10 μM PD98059 and
1.0 μM U0126) prevented the ARTN-induced increases
in p-Erk, while the inactive control compound, U0124
(1.0 μM), did not affect the ARTN-induced increase in
p-Erk (Figure 7A and 7B). LY294002 (10 μM), the inhi-
bitor of the PI-3K pathway, prevented the ARTN-
induced increases in p-Akt, while the inactive control
compound, LY303511 (10 μM), did not affect the
ARTN-induced increase in p-Akt (Figure 7A and 7C).
Capsaicin-stimulated release of iCGRP after a 10 min
exposure to ARTN was ~2-fold higher compared to
release without ARTN. The increase in stimulus-evoked
release with ARTN was unaffected by inhibition of MEK
by PD98059 and U0126 or inhibition of the PI-3K path-
way by LY294002 (Figure 7D). This result is despite the
fact that identical treatments with these inhibitors
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Page 7 of 22Figure 5 GDNF-activates the MAPK pathway and not the PI-3K pathway and sensitizes sensory neurons through the MAPK pathway.
A) This representative Western blot demonstrates changes in levels of p-Erk 1/2, Erk 1/2, p-Akt, Akt, and a-tubulin in DRG in response to a
10 minute incubation with 10 ng/mL GDNF and the subsequent prevention of these changes by inhibitors of the MAPK pathway (10 μM
PD98059 and 1 μM U0126) and the PI-3K pathway (10 μM LY294002). B and C) Densitometric analysis of three separate Western blots like that in
A probing for B) MAPK pathway components and C) PI-3K pathway components. D) Peptide release elicited by a 10 minute exposure to Hepes
buffer alone (open bar) or Hepes buffer containing 50 nM capsaicin (Cap; dark bars) is expressed as mean percent total peptide content of cells
in each well ± SEM (n = 12-18 wells per condition). GDNF and inhibitors.were included in the 10 minutes prior to and throughout capsaicin
exposure. Asterisks (*) indicate statistically significant differences in band density and iCGRP release between treatment groups and the no GDNF
condition using an ANOVA with Dunnett’s post-hoc test (p < 0.05). Ampersands (@) indicate statistically significant differences between the
10 ng/mL treatment condition and the condition containing the inhibitor listed below the graph using t-tests (p < 0.05). In all cases, release
stimulated by capsaicin was significantly higher than basal release.
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Page 8 of 22Figure 6 NRTN-activates the MAPK and PI-3K pathways and induces enhancement in the stimulated-release of iCGRP through the
PI-3K pathway. A) This representative Western blot demonstrated changes in levels of p-Erk 1/2, Erk 1/2, p-Akt, Akt, and a-tubulin in DRG in
response to a 10 minute incubation with 10 ng/mL NRTN and the subsequent prevention of these changes by inhibitors of the MAPK pathway
(10 μM PD98059 and 1 μM U0126) and the PI-3K pathway (10 μM LY294002). B and C) Densitometric analysis of three separate Western blots
like that in A probing for B) MAPK pathway components and C) PI-3K pathway components. D) Peptide release elicited by a 10 minute exposure
to Hepes buffer alone (open bar) or Hepes buffer containing 50 nM capsaicin (Cap; dark bars) is expressed as mean percent total peptide
content of cells in each well ± SEM (n = 12-18 wells per condition). Asterisks (*) indicate statistically significant differences in band density and
iCGRP release between treatment groups and the no NRTN condition using an ANOVA with Dunnett’s post-hoc test (p < 0.05). Ampersand (@)
indicates statistically significant differences between the 10 ng/mL treatment condition and the condition containing the inhibitor listed below
the graph using t-tests (p < 0.05). In all cases, release stimulated by capsaicin was significantly higher than basal release.
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Page 9 of 22Figure 7 ARTN-activates the MAPK and PI-3K pathways and induces enhancement in the stimulated-release of iCGRP through neither
the MAPK nor the PI-3K pathway. A) This representative Western blot demonstrated changes in levels of p-Erk 1/2, Erk 1/2, p-Akt, Akt, and
a-tubulin in DRG in response to a 10 minute incubation with 10 ng/mL ARTN and the subsequent prevention of these changes by inhibitors of
the MAPK pathway (10 μM PD98059 and 1 μM U0126) and the PI-3K pathway (10 μM LY294002). B and C) Densitometric analysis of three
separate Western blots like that in A probing for B) MAPK pathway components and C) PI-3K pathway components. D) Peptide release elicited
by a 10 minute exposure to Hepes buffer alone (open bar) or Hepes buffer containing 50 nM capsaicin (Cap; dark bars) is expressed as mean
percent total peptide content of cells in each well ± SEM (n = 12-18 wells per condition). Asterisks (*) indicate statistically significant differences
in band density and iCGRP release between treatment groups and the no ARTN condition using an ANOVA with Dunnett’s post-hoc test (p <
0.05). In all cases, release stimulated by capsaicin was significantly higher than basal release.
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Page 10 of 22prevented ARTN-induced activation of the MAPK and
PI-3K pathways, as measured by increases in p-Erk and
p-Akt levels. To investigate if either pathway, MEK/Erk
1/2 or PI-3K, alone was sufficient to mediate ARTN-
induced enhancement in the stimulated-release of
CGRP, the MEK inhibitor PD98059 (10 μM) and the PI-
3K inhibitor LY294002 (10 μM) were used in combina-
tion. When treated with both inhibitors, there was still
no effect on ARTN-induced sensitization (Figure 7D),
demonstrating the disconnect between increases in p-
Erk and p-Akt and the functional significance of the
MEK/Erk1/2 and PI-3K pathways for ARTN-induced
sensory neuronal sensitization.
There is emerging evidence that the Src family kinases
(SFKs), which are pathways initiated by activation of
Ret, NCAM, and Integrin b-1, play an important role in
sensory neuronal sensitization [39,40] and that the GFLs
activate the SFKs [26,38]. To evaluate the role of SFKs
in GFL-induced sensory neuronal sensitization, DRG
cultures were exposed to each of the GFLs and the
amount of phospho-SFKs (p-SFK), were measured with
a pan-SFK antibody. Each of the GFLs increases p-SFK
levels, and the pan-SFK inhibitor, PP2, at a concentra-
tion of 10 μM [41], prevented this increase (Figure 8A
and 8B). The inactive analogue of PP2, PP3, did not pre-
vent the GFL-induced increase in SFKs (Figure 8A and
8B). The pharmacological agents, PP2 and PP3, were
then added to the DRG cultures to determine the role
of SFKs in GFL-mediated enhancement of capsaicin sti-
mulated release of iCGRP. PP2 abolished the sensitiza-
tion of stimulus-evoked release by GDNF, NRTN, and
ARTN, while the inactive control, PP3, did not affect
any of the GFL-induced sensitization (Figure 8C). These
experiments suggest that activation of SFKs is involved
in GFL-induced sensitization. However, PP2 prevents
phosphorylation of many proteins, including Src [42],
the other SFKs, Fyn and Yes [26], and importantly, Ret
[26]. Therefore, siRNA targeted to c-Src specifically, and
n o tt h eo t h e rS F K s ,w a su s e da sat o o lt om o r es p e c i f i -
cally evaluate the role of the c-Src pathway in GFL-
induced sensitization. The c-Src siRNA (100 nM) was
added to the DRG cultures two days after plating and
remained in the culture media for 48 hours. Figure 9A,
B, and 9C show that the c-Src siRNA reduces c-Src
expression levels by ~80% and does not change Fyn
levels. Scramble siRNA did not affect c-Src or Fyn levels
(Figure 9A, B, and 9C). Although GFL-induced enhance-
ment in the stimulated-release of CGRP of sensory neu-
rons was still present after treatment with c-Src siRNA,
there was a reduction in the magnitude of enhancement
of release of iCGRP by each of the GFLs in cultures
exposed to c-Src siRNA compared to those exposed to
scramble siRNA (Figure 9D). c-Src siRNA did not alter
Ret expression or increases in p-Ret induced by GDNF
treatment (Figure 10A and 10B), while PP2 did prevent
p-Ret production induced by ARTN treatment (Figure
10C and 10D), indicating that the complete prevention
of enhancement in the stimulated-release of CGRP by
PP2 is not accomplished through inhibition of Src acti-
vation. The tyrosine kinase, Fyn, is a downstream effec-
tor of NCAM that is not activated by Ret [14]. To
further evaluate the role of the NCAM-initiated signal-
ing cascade in sensory neuron sensitization, Fyn expres-
sion was reduced by treatment of DRG with Fyn siRNA
(100 nM). Fyn siRNA treatment reduced Fyn levels by
~80% (Figure 11A and 11B). There was no difference in
Fyn levels between non-treated and scramble siRNA
treated DRG (Figure 11A and 11B), and Fyn siRNA did
not affect the level of the other SFK, c-Src (Figure 11C
and 11D). When the DRG cultures were treated with
Fyn siRNA, the GFL-induced actions on iCGRP release
mimicked the results seen with NCAM siRNA. GDNF-
induced enhancement in the stimulated-release of
CGRP was not affected, while NRTN and ARTN-
induced sensitization was still present, but the absolute
amount of NRTN- and ARTN-dependent enhancement
of stimulated-release of iCGRP was reduced
(Figure 11E). When the DRG cultures were treated with
both Ret siRNA and Fyn siRNA, the ARTN-induced
enhancement in the stimulated-release of CGRP was
abolished, while the NRTN-induced sensitization was
still present (but the absolute amount of NRTN-induced
enhancement of stimulated release of iCGRP was
reduced; Figure 11F). Since only 20-50% of DRG neu-
rons coexpress GFRa-2 and CGRP, changes in SFK
phosphorylation seen in the heterogeneous DRG popu-
lation may not correlate completely with changes in
CGRP release in this preparation. Together, these data
indicate that NCAM/Fyn signaling does play an impor-
tant role in the Ret-independent component of NRTN-
and ARTN-induced sensitization of sensory neurons but
that NRTN-induced responses may utilize yet a third
mode of activation.
The experiments detailed above demonstrate that each
of the GFLs have distinct, though overlapping, comple-
ments of signaling pathways for the induction of sensory
neuronal sensitization. GDNF induces enhancement in
the stimulated-release of CGRP in a Ret-dependent
manner through the MEK/Erk 1/2 pathway. NRTN
causes sensitization through the PI-3K pathway in both
a Ret-dependent manner and a Ret-independent manner
via the NCAM and Integrin b-1 receptors. ARTN
induces sensitization in a Ret-dependent and Ret-
independent manner, via the NCAM receptor. Down-
stream actions of ARTN may be mediated through PKC
activation (Dr. Weiguo Zhu, personal communication).
Interestingly, NRTN and ARTN induced increases in
pathways unnecessary for sensitization, demonstrating a
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Page 11 of 22Figure 8 GFL-induced enhancement in the stimulated-release of iCGRP is mediated by SFK pathway. A) This representative Western blot
demonstrated changes in levels of p-SFKs, SFK, and a-tubulin in DRG in response to a 10 minute incubation with 10 ng/mL GDNF, NRTN, and
ARTN and the subsequent prevention of these changes by an inhibitor of the SFK pathway (10 μM PP2). The inactive control compound for this
pathway was added as well (10 μM PP3). B) Densitometric analysis of three separate Western blots like that in A probing for SFKs. C) Peptide
release elicited by a 10 minute exposure to Hepes buffer alone (open bar) or Hepes buffer containing 50 nM capsaicin (Cap; dark bars) is
expressed as mean percent total peptide content of cells in each well ± SEM (n = 12-18 wells per condition). Asterisks (*) indicate statistically
significant differences in band density and iCGRP release between treatment groups and the no GFL condition using an ANOVA with Dunnett’s
post-hoc test (p < 0.05). Ampersands (@) indicate statistically significant differences between the GFL treatment and the PP2 treated condition
using a t-test (p < 0.05). In all cases, release stimulated by capsaicin was significantly higher than basal release.
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Page 12 of 22Figure 9 GFL-induced enhancement in the stimulated-release of iCGRP is mediated by the Src kinase pathway.A )T h i sr e p r e s e n t a t i v e
Western blot demonstrates reduction in levels of c-Src and no change in Fyn levels in DRG in response to Src siRNA treatment. B and C)
Densitometric analysis of three separate Western blots like that in A probing for B) c-Src and C) Fyn. D) Peptide release elicited by a 10 minute
exposure to Hepes buffer alone (open bar) or Hepes buffer containing 50 nM capsaicin (Cap; dark bars) is expressed as mean percent total
peptide content of cells in each well ± SEM (n = 12-18 wells per condition). Asterisks (*) indicate statistically significant differences in band
density and iCGRP release between treatment groups and the no GFL condition using an ANOVA with Dunnett’s post-hoc test (p < 0.05).
Ampersands (@) indicate statistically significant differences between the GFL treatment and the siRNA treated condition using a t-test (p < 0.05).
In all cases, release stimulated by capsaicin was significantly higher than basal release.
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Page 13 of 22Figure 10 SFK inhibition prevents Ret phosphorylation. A) This representative Western blot demonstrates that the increase in p-Ret induced
by 10 ng/mL GDNF is not prevented by either Scramble siRNA or c-Src siRNA. B) Densitometric analysis of three separate Western blots like that
in A probing for p-Ret. C) This representative Western blot demonstrates that twenty minute exposure of DRG to 10 ng/mL ARTN increased
p-Ret levels, and this increase was prevented by both Ret siRNA and the SFK inhibitor PP2. D) Densitometric analysis of three separate Western
blots like that in A probing for p-Ret. Asterisks (*) indicate statistically significant differences between treatment conditions and the no treatment
condition using an ANOVA with Dunnett’s post hoc testing (p < 0.05).
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Page 14 of 22Figure 11 ARTN-induced enhancement in the stimulated-release of iCGRP is mediated, in part, by Fyn-dependent pathways.A )T h i s
representative Western blot demonstrates that exposure of DRG to Fyn siRNA decreases Fyn levels, while Scramble siRNA does not change Fyn
levels. B) Densitometric analysis of three separate Western blots like that in A probing for Fyn. C) This representative Western blot demonstrates
that exposure of DRG to Fyn siRNA (100 nM) and scramble siRNA (100 nM) do not change c-Src levels. D) Densitometric analysis of three
separate Western blots like that in A probing for c-Src. E and F) Peptide release elicited by a 10 minute exposure to Hepes buffer alone (open
bar) or Hepes buffer containing 50 nM capsaicin (Cap; dark bars) is expressed as mean percent total peptide content of cells in each well ± SEM
(n = 12-18 wells per condition). Asterisks (*) indicate statistically significant differences in band density and iCGRP release between treatment
groups and the no GFL condition using an ANOVA with Dunnett’s post-hoc test (p < 0.05). Ampersands (@) indicate statistically significant
differences between the GFL treatment and the siRNA treated condition using a t-test (p < 0.05). In all cases, release stimulated by capsaicin was
significantly higher than basal release.
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Page 15 of 22definitive dissociation of pathway activation and func-
tional changes in the cell. The pathways of sensitization
by each of the GFLs are represented schematically in
Figure 12.
Conclusions
We have demonstrated for the first time functional con-
sequences of GFL-induced Ret-independent pathway
activation in neurons. We also have demonstrated disso-
ciation of pathway activation, as measured by increases
in the level of phosphorylated effector proteins, and
functional consequences of inhibition of these pathways
on sensitization.
Initiation of GFL-induced enhancement in the stimulated-
release of CGRP is accomplished through several and
distinct complements of cell surface receptors
Ret is the classic signaling partner of the GFL-GFRa
complex, but there is increased evidence from the litera-
ture that the GFLs can signal independently of Ret in
cells that lack Ret [43]. One other Ret-independent sig-
naling mechanism for the actions GDNF is directly
through the GFL-GFRa complex [44,45]. The GDNF-
GFRa complex can bind to Integrin b-1 [16]. We did
not demonstrate a Ret-independent component for
GDNF-induced enhancement in the stimulated-release
of CGRP. This could be accounted for by the use of dif-
ferent cell types and cell functions studied. GDNF
promoted ureteric branching, but not chemotactic
migration, independently of Ret [45], and embryonic
substantia nigra neurons were protected from 6-OH DA
damage through NCAM [14,16]. The effects of GDNF
in these cells were likely due to the growth promoting
effects of GDNF, distinct from sensitization. There is no
evidence for NRTN-induced, Ret-independent effects in
any cell type. Our demonstration of NRTN-induced,
Ret-independent pathway of sensitization is novel. The
NCAM-dependent actions of NRTN may be mediated
by the direct binding of NRTN with NCAM, since
GFRa-2 levels may be decreased in sensory neurons in
culture [3]. ARTN also alters sensory neuronal sensitiza-
tion through Ret-independent mechanisms [46,47]. The
normal electrophysiological functions of injured C-fibers
are recovered by exposure to ARTN. This recovery
occurs for C-fibers that express GFRa-3 but not Ret,
demonstrating these effects are Ret-independent [46].
Together, this suggests a role for Ret-independent
actions of NRTN and ARTN in sensory neurons.
GDNF-induced enhancement in the stimulated-release of
CGRP is mediated by the MAPK/Erk 1/2 pathway
GDNF activates the MAPK/Erk 1/2, the PI-3K, and the
Src kinase pathways [5,48]. GDNF robustly activated the
MAPK/Erk 1/2 and Src pathways, but not the PI-3K
pathway in our DRG cultures. MAPK/Erk 1/2 pathway
inhibitors, SFK inhibitors, and Src siRNA prevented
GDNF-induced enhancement in the stimulated-release
of CGRP, while inhibition of the PI-3K pathway did not.
Bron et al. observed PI-3K activation with exposure to
GDNF [48]. However, in this study the DRG were
Figure 12 Schematic of working model of the pathways of enhancement in the stimulated-release of CGRP by GDNF, NRTN, and ARTN.
This work was funded in part by NINDS R01 NS051668 (CMH) and a Young Investigator’s Award from the Children’s Tumor Foundation (BSS).
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Page 16 of 22exposed to high concentrations of GDNF (50 ng/mL
and higher), which could account for the PI-3K pathway
activation. Activation of PI-3K also could have occurred
through non-specific effects of GDNF through non-spe-
cific binding to the GFRa-2 receptor [49-51] at the
higher concentrations used.
There is additional evidence that GDNF can activate
SFKs in a Ret-independent manner [5,52] in DRG
from Ret deficient mice and two neuronal cell lines
that lack Ret expression (NIH3T3 and SHEP neurobal-
stoma), stably transfected with GFRa-1. When Ret was
inhibited using a specific siRNA, the GDNF-induced
sensitization was abolished. The differences between
previous reports of GDNF-induced, Ret-independent
actions and the data presented here could be the result
of the different developmental stage and type of cells.
Embryonic neurons and cell lines may be primarily
responding to growth promoting actions of GDNF,
which may use different complements of signaling
pathways and cell surface receptors, than adult primary
DRG preparations.
NRTN-induced enhancement in the stimulated-release of
CGRP is mediated by the PI-3K pathway
There is evidence for NRTN activation of MAPK, PI-3K,
and SFK pathways [35-37]. NRTN robustly activated all
three of these pathways. However, NRTN-induced sen-
sory neuronal sensitization was prevented by inhibition
of the PI-3K and SFK pathways, but not the MAPK
pathway. The downstream effector of NRTN-induced
sensitization was in all cases PI-3K.
ARTN-induced enhancement in the stimulated-release of
CGRP is mediated by neither the MAPK/Erk 1/2 pathway
nor the PI-3K pathway
ARTN also activates the MAPK, PI-3K, and SFK path-
ways [35-37]. Inhibition of any of these pathways could
prevent ARTN-induced enhancement in the stimu-
lated-release of CGRP. However, only Src inhibition
was able to reduce the amount of ARTN-induced sen-
sitization. Inhibitors of the MAPK/Erk 1/2 or the
PI-3K pathways did not prevent the ARTN-induced
sensitization even though they effectively reduced the
levels of p-Erk and p-Akt. Either of these pathways
may be sufficient, but neither necessary, for ARTN-
induced sensitization. There is evidence for the need
for both MAPK and PI-3K activation for neuronal pro-
tection by GDNF [53]. Addition of GDNF to B92 glial
cells prevented damage of these cells by high concen-
trations of ethanol through the MAPK and PI-3K path-
ways [53]. Inhibition of either pathway individually did
not reverse the effects of GDNF. The use of one inhi-
bitor of the MAPK/Erk 1/2 and one inhibitor of the
PI-3K pathway in combination did not affect the
enhancement in stimulated-release of iCGRP induced
by ARTN. These data demonstrate that Src is a likely
pathway important in ARTN-induced sensitization, but
that neither MAPK nor PI-3K is necessary for this sen-
sitization. While previous studies identified either or
both of these pathways as important in alteration of
neuronal function by ARTN [36-38], these studies
were conducted on motor neurons or glial cells, not
adult sensory neurons. These differences in cell type
could explain the different pathways activated.
Dissociation of intracellular signaling pathway activation
and induction of enhancement in the stimulated-release
of CGRP by these pathways
The work presented here demonstrates the dissociation
of pathway activation and function. NRTN and ARTN
induced increases in phosphorylated effector proteins
for the MAPK and PI-3K pathways, but these pathways
were unnecessary for NRTN- or ARTN-induced
enhancement in the stimulated-release of CGRP. NRTN
increases both p-Erk and p-Akt levels, but only inhibi-
tion of the PI-3K pathway prevented NRTN-induced
sensitization. ARTN increased the level of p-Erk and p-
Akt, however, inhibition of either of these pathways or
both pathways simultaneously did not prevent sensitiza-
tion. Previous work demonstrating the role of the MEK/
Erk1/2 and PI-3K pathways in sensory neuronal sensiti-
zation has been predicated on the fact that increases in
p-Erk and p-Akt are adequate surrogate measures for
function changes.
Possible physiologic purpose for different complements
of receptors and intracellular signaling pathways for
enhancement in the stimulated-release of CGRP by each
of the GFLs
Although GDNF, NRTN and ARTN were originally
thought to mediate all of their actions through the Ret
receptor and similar sets of intracellular signaling path-
ways, we have demonstrated that each of these GFLs
uses distinct complements of signaling pathways to sen-
sitize sensory neurons. There are three possible explana-
tions for these differences. First, each of the GFLs is
modulating the responses of sensory neurons innervat-
ing different tissues. The DRG is a heterogenous popu-
lation of neurons; in particular there are sensory
neurons that innervate the skin, the viscera, and the
musculoskeletal system. There is evidence that each of
the GFLs has specific and/or preferential populations of
sensory neurons on which they modulate responses
[54-58]. It is possible that each of the subtypes of pri-
mary afferents has distinct sets and abundances of
receptors (Ret, NCAM, and Integrin b-1) and signaling
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Page 17 of 22pathways available for the action of sensitization. Muscle
afferents and motor neurons, under certain circum-
stances, may express only Ret and GFRa-1 receptors
and preferentially use the c-Src kinase/MAPK/Erk 1/2
pathway for sensitization, while visceral afferents may
express GFRa-2, Ret, NCAM, and Integrin b-1 receptors
and preferentially use the SFK and Syk kinase signaling
cascades through the PI-3K pathway for sensitization.
ARTN responsive neurons may express only Ret,
NCAM, and GFRa-3 receptors and preferentially use
the Fyn kinase and c- Src kinase signaling cascade for
sensitization. Second, each of the specific GFRa recep-
tors may localize to different portions of the cell mem-
brane where different complements of receptors and
pathways are present. When the GFL-GFRa complex
binds its GFL, this complex recruits Ret into lipid rafts
and initiates signaling [59]. Inside lipid rafts, Ret signals
through SHC and Grb2 [60]. Outside lipid rafts, Ret sig-
nals through FSR2 [60]. Each of the GFLs could be acti-
vating different receptors and signaling pathways based
on compartmentalization of these receptors and path-
ways with individual GFRa receptors. Finally, each of
the GFLs may cause different structural changes in their
specific GFRa receptor subtype that allow different
interactions with Ret, NCAM, and Integrin b-1. It has
been shown that when the ARTN-GFRa-3 complex
translocates to Ret, it activates the MAPK pathway more
slowly and less robustly than when the GDNF-GFRa-1
complex translocates to this receptor [13]. This may be
because different tyrosine residues are available depend-
ing on the Ret configuration. This could partially explain
the differential complements of pathways used by each
of the GFLs to accomplish their sensory neuronal
sensitization.
GFLs can induce sensitization of sensory neurons in a
Ret-independent manner. Additionally, it is clear that
increases in phosphorylated effector proteins do not
establish a causal role for that effector system in func-
tional endpoints. Knowledge of the signaling pathways
a v a i l a b l ef o ru s eb yt h eG F L sm a yb eu s e f u li nb e t t e r
understanding and control of the pathophysiological




The mice used for all experiments, C57BL/6 mice, were
purchased from Harlan Laboratories (Indianapolis, IN)
and/or bred and housed in the Indiana University
Laboratory Animal Research Center (LARC). All mice
were adults, between three and six months in age. All
experiments were performed in accordance with
National Institutes of Health Guide for Care and Use of
Laboratory Animals. All procedures were reviewed and
approved by the Indiana University School of Medicine
Institutional Animal Care and Use Committee. Capsai-
cin was purchased from Sigma Chemical Company (St.
Louis, MO) and was first dissolved in 1-methyl,2-pyrro-
lidinone (Aldrich Chemical Co., Milwaukee, WI) to a
concentration of 10 mM. It was then serially diluted to
a concentration of 50-500 nM in the appropriate release
buffer as noted below. Horse serum, F-12 medium,
L-glutamine, and penicillin/streptomycin were pur-
chased from Invitrogen (Carlsbad, CA, USA). NGF was
purchased from Harlan Bioproducts for Science, Inc.
(Indianapolis, IN, USA). Collagenase, poly-D-lysine,
laminin, 5-fluoro-2-deoxyuridine, uridine and standard
laboratory chemicals were from Sigma (St. Louis, MO,
USA). Antibody to calcitonin gene-related peptide
(CGRP) was generously provided by Michael R. Vasko
(Indiana University School of Medicine, Indianapolis,
IN, USA and originally produced by Michael J. Iadarola,
NIH). The GFLs were purchased from Peprotech (Rocky
Hills, NJ). The siRNA constructs were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA) and
were all pooled siRNAs except for the Src and scramble
siRNAs (not pooled siRNAs) which were developed by
Eric L. Thompson in Dr. Michael L. Vasko’s laboratory
(Indiana Univ. School of Medicine) and created by
Dharmacon, Inc (Lafayette, CO, USA). An siRNA
designed as a scramble for APE1, a multifunctional
DNA repair enzyme, was used as an siRNA transfection
control, as this control has been used in several sets of
experiments in the Hingtgen, Vasko, and Kelley labora-
tories and has not shown activity against any protein of
interest in any of these studies [61,62]. The Ret protein
control, isolated from mice, was purchased from Santa
Cruz Biotechnology. The sources, dilutions, and place of
purchase of each of the primary antibodies are listed
below. They are Ret: rabbit polyclonal primary antibody,
1:500 titer, Santa Cruz Biotechnology; p-Ret: rabbit poly-
clonal primary antibody, 1:300 titer, Santa Cruz Biotech-
nology; a-tubulin: mouse monoclonal antibody, 1:1,000
titer, Sigma; NCAM: rabbit polyclonal primary antibody,
1:500 titer, Santa Cruz Biotechnology; Integrin b-1:
mouse monoclonal primary antibody, 1:300 titer, Santa
Cruz Biotechnology; p-Erk 1/2: mouse monoclonal pri-
mary antibody, 1:500 titer, Cell Signaling Technologies;
Erk 1/2: rabbit polyclonal primary antibody, 1:900 titer,
Cell Signaling Technologies; p-Akt: mouse monoclonal
primary antibody, 1:500 titer, Cell Signaling Technolo-
gies; Akt: rabbit polyclonal primary antibody, 1:800 titer,
Cell Signaling Technologies; p-SFKs: rabbit polyclonal
primary antibody, 1:500 titer, Cell Signaling Technolo-
gies; SFK: rabbit polyclonal primary antibody, 1:500
titer, Cell Signaling Technologies; c-Src: mouse mono-
clonal primary antibody, 1:500 titer, Santa Cruz Biotech-
nology; Fyn: mouse monoclonal primary antibody, 1:300
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Page 18 of 22titer, Santa Cruz Biotechnology. The sources, dilutions,
and place of purchase of each of the primary antibodies
are listed below. They are goat anti-rabbit secondary
antibody, 1:25,000 titer, Jackson Laboratories and goat
anti-mouse secondary antibody, 1:10,000 titer, Jackson
Laboratories.
Preparation of dorsal root ganglia (DRG) cultures
Dorsal root ganglia (DRG) from adult mice were used to
establish sensory neuronal cultures. Briefly, the DRG
were removed from adult mice and prepared as pre-
viously published [4]. Cells were plated in wells of
24-well Falcon culture dishes coated with poly-D-lysine
and laminin at a density of 30,000-50,000 cells/well.
Cultures were maintained at 37°C in a 5% CO2 atmo-
sphere in F12 media supplemented with 2 mM gluta-
mine, 50 μg/mL penicillin and streptomycin, 10%
heat-inactivated horse serum and mitotic inhibitors (50
μM 5-fluoro-2-deoxyuridine and 150 μM uridine). NGF,
at a concentration of 30 ng/mL, was added to this media.
Growth medium was changed every 2-3 days, and the
added NGF removed 48 hrs prior to all experiments.
Stimulated-Release of iCGRP
Measurement of stimulus-evoked release and content of
immunoreactive CGRP (iCGRP) from isolated sensory
neurons was accomplished as previously published [4].
After 5-7 days in culture, culture media was removed
from the sensory neurons in culture and the basal or
resting release of iCGRP measured from cells incubated
for 10 minutes in HEPES buffer consisting of (in mM):
25 HEPES, 135 NaCl, 3.5 KCl, 2.5 CaCl2, 1 MgCl2,3 . 3
dextrose, and 0.1% (w/v) bovine serum albumin, pH 7.4,
a n dm a i n t a i n e da t3 7 ° C .T h ec e l l sw e r ei n c u b a t e di n
HEPES buffer containing stimulus (capsaicin, 50 nM)
for 10 minutes, and then incubated again with HEPES
buffer alone to reestablish resting release levels. The
amount of iCGRP released in each incubation was mea-
sured by radioimmunoassay (RIA). The minimum
amount of iCGRP detected by the RIA is 5 fmol with a
95% confidence interval [63]. After the release protocol,
the remaining peptide content in each well was deter-
mined by exposing the cells to 2 N acetic acid for
10 minutes. Aliquots of this incubation were diluted in
HEPES and iCGRP was determined by RIA. The total
content of iCGRP in the DRG cultures was not altered
by any of the siRNA or pharmacological treatments
( d a t an o ts h o w n ) .T h er e l e a s eo fi C G R Pd u r i n gt h e
10 min incubation period is expressed as percent of the
total content. GFLs and pharmacological inhibitors were
added in the basal incubation period (10 minutes) and
in the stimulated incubation period (10 additional min-
utes) for a total exposure time of 20 min. A minimum
of three different preparations were used for each
condition, including growth factor application and phar-
macological inhibitor application.
Treatment of DRG with siRNA and/or Pharmacological
Inhibitors
When using siRNA to inhibit specific protein produc-
tion, these molecules were added two days after DRGs
were plated. Metafectine Pro (Biontex Laboratories,
Martinsried, Planegg, Germany), the transfection agent,
was diluted to a titer of 1:250 in each well in Optimem
reduced serum media (Invitrogen, Carlsbad, CA). The
siRNA molecules were also diluted in Optimem. The
Metafectine and siRNA dilutions were allowed to sit at
room temperature for two minutes then mixed at a 1:1
ratio and allowed to incubate at room temperature for
20 minutes. The mixture was added to each well so that
the final concentration of the siRNA was 100 nM. The
following day, F12 media containing NGF and normocin
was added to the wells to a final volume 1.0 mL. Twenty
four hours later, all the media was removed from the
wells and 500 μl of normal growth media (F12 media
supplemented with F12 media supplemented with gluta-
mine, penicillin and streptomycin, horse serum and
mitotic inhibitors as indicated above) was added. Cells
were maintained in F12 media without supplemental
NGF for the 48 hours prior to use in experiments.
Isolation of protein samples from sensory neurons in
culture and Western blotting
Sensory neurons from DRG from adult mice plated on 12
well Falcon plates were maintained in culture for 5-7 days.
Cells were then washed with Hepes buffer and treatments
added as indicated below. After treatment, the cells were
washed once with PBS, then 500 μl of PBS added to each
well. The wells were then scraped and the cells transferred
in solution to ependorf tubes. The tubes were centrifuged
at 16,000 rpm for 20 minutes. The supernatant was
removed and the remaining pellet was either placed on
dry ice and transferred immediately to a freezer at -80°C
or protein content quantified immediately.
For protein quantification, DRG pellets were resus-
pended in 50 μl of general lysis buffer (1mM Na pyro-
phosphate, 50 mM Hepes, 1% Triton X-100, 50 mM
NaCl, 50 mM NaF, 5 mM EDTA, and 1 mM Na orthova-
nadate) supplemented with proteinase inhibitor mixture
(aprotinin, leupeptin, pepstatin, PMSF; Calbiochem, Sand
Diego, CA, USA). The resuspended protein was incu-
bated for 15 minutes on ice with frequent vortexing. The
suspension was Sonicated 3 times for 10 seconds each at
45 watts. The suspension was then centrifuged at 4,000g
for 2 minutes. The supernatant was removed and stored
at -20°C. The protein was quantified using a BCA Protein
Assay Kit (Thermo Scientific, Rockford, IL, USA) and
read on a Wallac plate reader at 595 nm for 1.0 s.
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with loading buffer (Ambion, Austin, TX, USA) contain-
ing b-mercaptaethanol to a final volume of 60 μla n d
denatured at 70°C foir 10 minutes. The samples were
then incubated at room temperature for 15 minutes and
loaded into wells of precast 10% SDS-PAGE gels
(Biorad, Philadelphia, PA, USA) containing 10 lanes.
The samples were run on the gels, which were con-
nected to a Biorad power source, for 2 hours at 115 mV
at room temperature. While the gel was running, filter
papers (Biorad, Philadelphia, PA, USA), fiber pads
(Biorad, Philadelphia, PA, USA), and PVDF transfer
membranes (Millipore, Darwinweg, the Netherlands)
were soaked in 1X transfer buffer (25 mM Tris at pH
7.5; 192 mM Glycine; 5-20% methanol). Prior to soaking
in transfer buffer, the PVDF membranes were soaked in
100% methanol for 1 min and washed extensively with
ddH20. SDS-PAGE gels were placed on transfer mem-
branes within a transfer cartridge and transferred in a
Biorad system at 100 mV for 1 hour at room tempera-
ture with an ice pack in the apparatus.
After transfer, the membranes were removed from the
apparatus and placed in 10% powered skim milk (EMD,
Gibbstown, NJ, USA) in 1X TBS (20 mM Tris PH 7.5;
150 mM NaCl as a blocking solution for 1 hour at room
temperature. Then, the blocking solution was discarded
and the membranes placed in 5% milk in TBST
(TBS containing 0.1% Tween-20) containing primary
antibodies at concentrations of 1:200 to 1:1,000. The
membranes were incubated in this solution overnight at
4°C. Several short washings and three 10 minute wash-
ings were accomplished with TBST after the overnight
incubation. Secondary antibody, at concentrations from
1:4,000 to 1:25,000, in 5% milk in TBST was applied to
the membrane for 1 hour at room temperature. A simi-
lar set of washings was done after the secondary anti-
body exposure, then the membranes were blotted dry
and placed in the combination of solutions for enhanced
chemiluminescence (ECL; Thermo Scientific, Rockford,
IL, USA) for 3 minutes. The membranes were placed in
clear plastic sheets and inserted into X-ray cartridges
(Soyee Products, New York City, NY, USA). Once in
complete darkness, X-ray films (Midwest Scientific, St.
Louis, MO, USA) were placed inside the cartridge and
exposed for 5 seconds, 30 seconds, 1 minute, 5 minutes,
and 15 minutes. Films were first placed in Kodak/GBX
developer (Thermo Fisher Scientific, Pittsburgh, PA,
USA) for 30 seconds per side, then washed in cold
water for 1 minute per side. The films were fixed in
Kodak/GBX fixing solution (Thermo Fisher Scientific,
Pittsburgh, PA, USA) for 30 seconds per side, washed
again, and allowed to dry for 2 hours.
The dried films were scanned as JPEG files and densi-
tometric measurements made with Un-Scan It (Orem,
UT, USA). Immunoreactive bands of interest were nor-
malized to a-tubulin bands.
Statistical Analyses
Results, represented as percent total content of iCGRP,
are expressed as the mean ± standard error of the mean
(SEM). All differences were compared with one-way
analyses of variance (ANOVAs) and Dunnett’sp o s th o c
analysis or Student t-tests, as indicated. A p value of
<0.05 was used to indicate statistical significance.
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